SER
Serina Therapeutics, Inc.
stockNYSEAMERICAN
agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in development include agex-bat1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as type ii adult-onset diabetes; and agex-vasc1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. its lead drug-based therapeutic candidate in discovery is agex-itr1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. in addition, the company markets human embryonic stem cells; and genecards database suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. agex therapeutics, inc. ha
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.38 | 2026-11-06 | +1.45% | 2.829 |
| 1M | 1.82 | 2026-10-13 | -23.08% | 0.452 |
| 3M | 2.85 | 2026-08-13 | -50.88% | 0.846 |
| 6M | 1.56 | 2026-05-13 | -10.26% | 1.082 |
| 1Y | 3.92 | 2025-11-13 | -64.29% | 1.268 |
| 2Y | 5.00 | 2024-11-13 | -72.00% | — |
Serina Therapeutics, Inc. (NYSEAMERICAN:SER) stock price today is $1.40, and today's volume is 10,779. SER is down 0.709% today. The 30 day average volume is 60,687. SER market cap is $35.56M with 25.40M shares outstanding.